The SURPASS program established efficacy in type 2 diabetes across multiple comparators, including head-to-head superiority versus semaglutide on HbA1c reduction in SURPASS-2 (Fras et al., NEJM, 2021)
The confidence interval range 5.78 to 13.60 kg for the semaglutide and tirzepatide group reflects the degree of variation that existed even within a controlled study population
Peptide therapy is not for everyone and only you and your physician can determine if this is right for you
Dispensed under licensed supervision Sourced from authorized distributors with batch verification
Starting patients on GLP-1s is one aspect but we should also see how many can stay on it long term
Based on a study conducted on 2,539 adults, after 12 weeks of Tirzepatide treatment, researchers categorized participants as "early responders" if they had lost at least 5% of their body weight, and as "slow responders" if they had lost less than 5% of their body weight